Recruiting PHASE2 INTERVENTIONAL 4-arm NCT05607004

(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer (EVANGELINE)

A Phase 2 Trial of (Z)-Endoxifen + Goserelin as Neoadjuvant Treatment for Premenopausal Women With ER+, HER2-, Breast Cancer

Sponsor: Atossa Therapeutics, Inc.

Conditions Breast Neoplasms Estrogen-receptor-positive Breast Cancer HER2-negative Breast Cancer Invasive Breast Cancer

Interventions (Z)-endoxifen goserelin

Updated 18 times since 2022 Last updated: Oct 29, 2025 Started: Feb 14, 2023 Primary completion: Nov 30, 2026 Completion: Apr 30, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Breast Neoplasms and Estrogen-receptor-positive Breast Cancer, this trial is actively recruiting participants. The trial is conducted by Atossa Therapeutics, Inc. and has accumulated 18 data snapshots since 2023. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

18 versions recorded

Nov 2025 — Present [monthly]

Recruiting PHASE2
Sep 2025 — Nov 2025 [monthly]

Recruiting PHASE2
Aug 2025 — Sep 2025 [monthly]

Recruiting PHASE2
May 2025 — Aug 2025 [monthly]

Recruiting PHASE2
Mar 2025 — May 2025 [monthly]

Recruiting PHASE2

▶ Show 13 earlier versions

Nov 2024 — Mar 2025 [monthly]

Recruiting PHASE2
Oct 2024 — Nov 2024 [monthly]

Recruiting PHASE2
Sep 2024 — Oct 2024 [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2
May 2024 — Jul 2024 [monthly]

Recruiting PHASE2
Feb 2024 — May 2024 [monthly]

Recruiting PHASE2
Nov 2023 — Feb 2024 [monthly]

Recruiting PHASE2
Jul 2023 — Nov 2023 [monthly]

Recruiting PHASE2
May 2023 — Jul 2023 [monthly]

Recruiting PHASE2
Apr 2023 — May 2023 [monthly]

Recruiting PHASE2
Mar 2023 — Apr 2023 [monthly]

Recruiting PHASE2
Feb 2023 — Mar 2023 [monthly]

Recruiting PHASE2
Dec 2022 — Feb 2023 [monthly]

Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Atossa Therapeutics, Inc.
InClin

Data source: Atossa Therapeutics, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Chicago, United States , Detroit, United States , Edgewood, United States , Houston, United States , Jacksonville, United States , Los Angeles, United States , Midlothian, United States , Nashville, United States , Phoenix, United States , Rochester, United States and 5 more locations